Evaluation of prostatic specific antigen (PSA) before and after prostate biopsy. Could this change define the existence of prostate cancer?

• Conditions: Prostate cancer; Cancer - Prostate

• Registration Number: ACTRN12613000716763
• Lead Sponsor: Gennimatas General Hospital of Thessaloniki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-07-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Male
• Target Recruitment: 210

Inclusion Criteria

Serum PSA > 4 ng/ml or abnormal DRE findings

Exclusion Criteria

Antiplatelet or anticoagulant medication <5 days before prostate biopsy
Bleeding disorder
Active UTI
Recent urethra catheterization due to acute retention (< 1 month)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Estimate the PSA change ratio before and after prostate biopsy between two groups of patients. Based on the result of biopsy group A is comprised of patients with benign prostate hyperplasia while group B is comprised of patients with prostate cancer.[PSA is going to be measured one day before prostate biopsy and one hour after the last biopsy core. The PSA change ratio is defined as the ratio of post-biopsy total serum PSA to pre-biopsy serum PSA. ]